Arcturus TherapeuticsARCT
ARCT
About: Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the research and development segment of medical applications for nucleic acid-focused technology. The company's product pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU and LUNAR-COV19.
Employees: 180
0
Funds holding %
of 6,831 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
39% more call options, than puts
Call options by funds: $5.9M | Put options by funds: $4.24M
16% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 49
3.49% less ownership
Funds ownership: 101.54% [Q2] → 98.05% (-3.49%) [Q3]
4% less funds holding
Funds holding: 170 [Q2] → 164 (-6) [Q3]
8% less capital invested
Capital invested by funds: $666M [Q2] → $615M (-$50.5M) [Q3]
17% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 29
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$41
142%
upside
Avg. target
$52
206%
upside
High target
$63
271%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
BTIG Thomas Shrader 29% 1-year accuracy 2 / 7 met price target | 142%upside $41 | Buy Initiated | 28 Jan 2025 |
HC Wainwright & Co. Ed Arce 49% 1-year accuracy 81 / 165 met price target | 271%upside $63 | Buy Reiterated | 13 Jan 2025 |
Financial journalist opinion
Based on 4 articles about ARCT published over the past 30 days
Neutral
Business Wire
2 days ago
Meiji Seika Pharma Receives Approval for Adding Domestic Manufacturing Sites in Japan for KOSTAIVE®, a Self-amplifying mRNA Vaccine Against COVID-19
TOKYO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan, President and Representative Director: Daikichiro Kobayashi) announced today that it has received approval for a partial amendment to the manufacturing and marketing approval of “KOSTAIVE® for Intramuscular Injection,” a self-amplifying mRNA vaccine for protection against COVID-19, to include domestic manufacturing sites in Japan. Meiji Seika Pharma and ARCALIS Co., Ltd. (Headquarters: Minami-soma City, Fukushima.
Neutral
Business Wire
3 days ago
Arcturus Therapeutics to Present at Guggenheim Securities SMID Cap Biotech Conference
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the Company will participate at a fireside chat hosted by Guggenheim Securities SMID Cap Biotech Conference in New York, on Thursday, February 6, 2025, at 10:30 a.m. Eastern Time. Webcast link can be found.
Neutral
Business Wire
3 weeks ago
Arcturus Therapeutics Announces Initiation of Phase 1 H5N1 Flu Vaccine Trial
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced the initiation of the Company's Phase 1 study of ARCT-2304, a self-amplifying mRNA (sa-mRNA) vaccine candidate, also known as LUNAR-H5N1, for active immunization to prevent pandemic influenza disease caused by H.
Neutral
Business Wire
3 weeks ago
Arcturus Therapeutics Announces Initiation of Dosing in Phase 2 Multiple Ascending Dose Studies for Cystic Fibrosis (CF) and Ornithine Transcarbamylase (OTC) Deficiency
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the first CF and OTC deficiency participants initiated dosing in December 2024, in the Company's Phase 2 multiple ascending dose studies. Each participant in the Phase 2 CF study (NCT06747858) is expected t.
Neutral
Business Wire
1 month ago
Arcturus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that Joseph Payne, President & Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, on Wednesday, January 15, 2025, at 9:45 a.m. Pacific Time. A webcas.
Neutral
Business Wire
2 months ago
Arcturus Therapeutics to Attend Upcoming Investor Conferences
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the Company will participate in the following investor conferences: Piper Sandler 36th Annual Healthcare Conference (Fireside Chat) Tuesday, December 3, 2024 (4:30 p.m. ET) Citi's 2024 Global Healthcare Con.
Neutral
Business Wire
2 months ago
Arcturus Therapeutics to Present at Jefferies London Healthcare Conference
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the Company will present at Jefferies London Healthcare Conference in London, on Wednesday, November 20, 2024, at 9:30 am GMT. A webcast and replay of the presentation will be available on the Investor Rela.
Negative
Seeking Alpha
2 months ago
Arcturus: LUNAR-CF For CF Presses On With 1st Half Of 2025 Interim Data
Interim results from phase 2 proof-of-concept study, using LUNAR-CF for treatment of patients with Cystic Fibrosis, expected 1st half of 2025. The global Cystic Fibrosis market size is projected to reach $62.57 billion by 2032. Interim results from phase 2 proof-of-concept study, using LUNAR-OTC for treatment of patients with OTC Deficiency, expected 1st half of 2025.
Neutral
Business Wire
2 months ago
Meiji Seika Pharma Announces Investment in ARCALIS, Inc.
TOKYO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan, President and Representative Director: Daikichiro Kobayashi; hereinafter referred to as "Meiji Seika Pharma") today announced its investment in ARCALIS, Inc. (Headquarters: Minami-soma City, Fukushima Prefecture; President: Satoshi Takamatsu; hereinafter referred to as "ARCALIS"). ARCALIS is a joint venture between Axcelead, Inc., which manages a group of world-class pharmaceutical and healthcare platform companie.
Neutral
Business Wire
2 months ago
Arcturus Therapeutics Receives Clearance from FDA to Begin H5N1 Pandemic Flu Vaccine Clinical Trial
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has issued a “Study Can Proceed” notification for the Company's Investigational New Drug (IND) application, ARCT-2304, a self-amplifying mRNA (sa-mRNA) vaccine ca.
Charts implemented using Lightweight Charts™